Grants

Major funds from public R&D Grants

Currently running

logo_cost_24Jul2017

Catalyzing transcriptomics research in cardiovascular disease

Name of beneficiary: Pharmahungary 2000 Kft., member of Pharmahungary Group

Acronym: CardioRNA

Short description of project: Pharmahungary Group joins COST Action titled CardioRNA – “Catalyzing transcriptomics research in cardiovascular disease”. The COST Action was proposed by Cardiolink Board Members and co-proposed by other 19 Cardiolinc members and partners.

The aim of the CardioRNA COST Action is to accelerate the understanding of transcriptomics in cardiovascular disease and further the translation of experimental data into practical applications for diagnostics and therapies to improve personalized medicine.

The human transcriptome, which is the set of all RNA produced in a cell, is much more complex than previously thought and the lack of dialogue between researchers and industrials and consensus on guidelines to generate data make it harder to compare and reproduce results. CardioRNA aims to provide opportunities for collaboration between stakeholders from complementary backgrounds, allowing the functions of different RNAs and their interactions to be more rapidly deciphered in the cardiovascular context for translation into the clinic.

Grant identification number: CA17129

logo_cost_24Jul2017

Realising the therapeutic potential of novel cardioprotective therapies

Name of beneficiary: Pharmahungary 2000 Kft., member of Pharmahungary Group

Acronym: EU-Cardioprotection

Short description of project: The main challenge is to improve the translation of novel cardioprotective therapies shown to be effective in the pre-clinical setting into the clinical arena for patient benefit. This COST Action (termed EU-CARDIOPROTECTION) aims to address this challenge by setting up a Europe-wide network of research centers tasked with: (1) the discovery of new therapeutic targets and innovative strategies for cardioprotection; (2) testing the effects of combination therapy to target multiple signaling pathways both within and outside the cardiomyocyte; 3) investigating the effects of confounders (co-morbidities and co-medications) on cardioprotection; (4) multi-center pre-clinical and clinical testing of novel cardioprotective therapies.

Grant identification number: COST CA16225

nkfih_national-innovation-office_logo_21dec2016

Synthesis, chemoinformatic development, optimization and preclinical testing of matrix metalloproteinase-2 inhibitors for cardioprotection.

Awarded by National Research, Development, and Innovation Office of Hungary and Department of Science & Technology of India

Name of beneficiary: Pharmahungary 2000 Kft., member of Pharmahungary Group

Project title: Synthesis, chemoinformatic development, optimization and preclinical testing of matrix metalloproteinase-2 inhibitors for cardioprotection

Total financial support: 164.000 EUR

Short description of project: This project is aimed to develop effective matrix metalloproteinase-2 inhibitors to treat myocardial infarction one of the leading cause of death and morbidity in India and Hungary. The project will be performed in collaboration of three research teams including a small-medium R&D enterprise (SME) in Hungary (see www.pharmahungary.com). It is planned to design, synthesize, study of novel substituted methylamino azole derivatives as Matrix Metalloproteinase (MMPs) inhibitors.

Planned project duration: 2016-2019, planned project end-date: November 1, 2019

Grant identification number: TÉT_15_IN-1-2016-0068

NSZPlogo_final_20170410jpg

National Heart Program: Research and innovation in diagnostics and therapy of ischemic heart disease and heart failure

Short title: National Heart Program

Name of beneficiary: Pharmahungary 2000 Kft., member of Pharmahungary Group

Total financial support for consortium: 3.299.426.997 HUF (approx. 10.686.405 EUR)

Rate of support: 90,50%

Background: In Hungary ischemic heart disease and heart failure are the leading cause of death. The objective of the grant is to develop therapies that reduce death by cardiovascular diseases.
Implementation: Cardiology research group of Semmelweis University (including clinical, pharmacology, bio-physics, inflammation-immunology, and bioinformatics researchers) and 4 R&D companies including Pharmahungary Group will implement the program. The consortium will develop innovative diagnostic and therapeutic approaches as well as novel products and services via interdisciplinary, integrated translational (from basic research to epidemiology) R&D projects.
Outcomes: Development of innovative R&D platforms based on in vitro and in vivo models, development of new diagnostic imaging equipment and bioinformatics solutions, identification of cost effective diagnostic and therapeutic molecular targets, screening of hidden cardiotoxicity of therapies, personalized risk assessment by multiomics analysis, novel cardiovascular therapies by medical devices, and medical guidelines.

Planned project duration: December 1, 2016 – November 30, 2019

Grant identification number: NVKP_16-1-2016-0017

For more information on the members of the consortium, see website.

 

Closed grants

 

Protect title: Maintenance and validation of the European regional patent application for the invention titled „Use of biglycan or enhancers of biglycan activity in the preparation of pharmaceutical compositions”. 

Name of beneficiary: Pharmahungary 2000 Kft., member of Pharmahungary Group

Total financial support: 2.337.200 HUF

Rate of support: 100%

Short description of project: The aim of this grant was to maintain and validate the European regional patent application for the invention titled „Use of biglycan or enhancers of biglycan activity in the preparation of pharmaceutical compositions”. For more information see: www.biglycan.com.

Project end date: December 5, 2017

Grant identification number: GINOP-2.1.3-15-2015-00024

 

infarnosys

SME Instrument Phase I winner

Project title: Novel biomarker diagnostic system for the assessment of the prognosis of acute myocardial ischemia/reperfusion injury and infarction and the effectiveness of the treatment

Short title: Infarnosys™

Short description of project: Novel biomarker diagnostic method and assay kit that will help clinical doctors in an early diagnosis of cardiac events and to evaluate the severity of injury caused by an infarction, and more importantly, the effectiveness of its treatment. Therefore, the technology will also contribute to a better planning of treatments.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 698297.

Purchase and installation of a small-animal ultrasonic imaging system, Baross Gabor program, National Office for Research and Technology (INPHARMA project, awarded for 2010)

Development of Innovative technology platform for the preclinical screening of metabolic diseases. Baross Gabor program, National Office for Research and Technology (METABBET project, awarded for the period of 2009-2011)

Technology transfer support of the cardiovascular R&D projects of Pharmahungary. Baross Gabor program, National Office for Research and Technology, awarded for 2009.

Development of “dietary foods for special medical purposes” for patients suffering from diabetes, atherosclerosis and coronary heart disease. National Technology Platform (MED-FOOD project, awarded for the period of 2008-2012)

Platform of mouse and human embryonic stem cell-derived cardiomyocyte test systems for drug development. Jedlik Anyos Grant (ES2HEART project, awarded for the period of 2008-2010)

Development of drug candidates based on genomics and chemoinformatics against myocardial infarction: inhibitors of matrix metalloproteinases. Jedlik Anyos Grant (NKFP_06_A1_MMP_2006 project, awarded for the period of 2007-2010). For further information: www.mmpharma.com.

Modulation of peroxynitrite-induced myocardial damage by pharmacological and gene therapies, and development of clinical  applications of peroxynitrite markers. GVOP Grant (GVOP-331-2004-04-0095_30, awarded for the period of 2005-2007)